Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company's products include OPDIVO intravenous infusions for treating malignant tumor; KYPROLIS, a proteasome inhibitor for intravenous injection; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Glactiv and FORXIGA tablets for type II diabetes; Kinedak tablets to treat diabetic peripheral neuropathy; Recalbon tablets to treat osteoporosis; ORENCIA injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease treatment; Onoact injections for the treatment of tachyarrhythmia; Staybla tablets for overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; Onon capsules and dry syrups for the treatment of bronchial asthma and allergic rhinitis; and Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis. It is also developing products for gastric, colorectal, small and non-small cell lung, head and neck, urothelial, esophageal, ovarian, biliary tract, hematologic cancers; and hodgkin lymphoma, hepatocellular carcinoma, glioblastoma, malignant pleural mesothelioma, multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, solid tumor, central nervous system lymphoma, primary testicular lymphoma, virus positive/negative solid carcinoma, chronic myeloid leukemia, cancer anorexia/cachexia, melanoma, pheochromocytoma, acute leukemia, juvenile idiopathic arthritis, lupus nephritis, untreated rheumatoid arthritis, primary sjögren syndrome, polymyositis/dermatomyositis, chronic heart failure, tachyarrhythmia, ventricular arrhythmia, sepsis, hepatitis C, parkinson's disease, overactive bladder, osteoarthritis, sjögren syndrome, and underactive bladder. Ono Pharmaceutical Co., Ltd. has collaboration agreements with Eisai Co., Ltd. and Schrödinger Inc., and Merus N.V. The company was founded in 1717 and is headquartered in Osaka, Japan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone816-6263-5670
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.60 billion
Profitability
Miscellaneous
Employees3,480
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Ono Pharmaceutical (OTCMKTS:OPHLF) Frequently Asked Questions
What is Ono Pharmaceutical's stock symbol?
Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."
When is Ono Pharmaceutical's next earnings date?
Has Ono Pharmaceutical been receiving favorable news coverage?
Media headlines about OPHLF stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ono Pharmaceutical earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Ono Pharmaceutical.
Who are some of Ono Pharmaceutical's key competitors?
Some companies that are related to Ono Pharmaceutical include ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Bausch Health Companies (BHC) and Beigene (BGNE).
What other stocks do shareholders of Ono Pharmaceutical own?
Who are Ono Pharmaceutical's key executives?
Ono Pharmaceutical's management team includes the folowing people:
- Mr. Gyo Sagara, Pres, CEO & Representative Director
- Yukio Tani, Corp. Officer & Director of Corp. Communications
- Mr. Hiroshi Ichikawa, Exec. Director of Sales & Marketing and Bus. Unit Director of Primary Care Bus. Unit
- Toichi Takino Ph.D., Corp. Officer and Exec. Director of Corp. Devel. & Strategy
- Mr. Kei Sano, Sr. Exec. Officer, Exec. Director of Corp. Mgt., Director - Product Strategy Dept. & Director
How do I buy shares of Ono Pharmaceutical?
Shares of OPHLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ono Pharmaceutical's stock price today?
One share of OPHLF stock can currently be purchased for approximately $18.38.
How big of a company is Ono Pharmaceutical?
Ono Pharmaceutical has a market capitalization of $9.45 billion and generates $2.60 billion in revenue each year. The company earns $464.98 million in net income (profit) each year or $0.90 on an earnings per share basis. Ono Pharmaceutical employs 3,480 workers across the globe.View Additional Information About Ono Pharmaceutical.
What is Ono Pharmaceutical's official website?
How can I contact Ono Pharmaceutical?
Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The company can be reached via phone at 816-6263-5670.
MarketBeat Community Rating for Ono Pharmaceutical (OTCMKTS OPHLF)
MarketBeat's community ratings are surveys of what our community members think about Ono Pharmaceutical and other stocks. Vote "Outperform" if you believe OPHLF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHLF will underperform the S&P 500 over the long term. You may vote once every thirty days.
